Harvard Bioscience will announce Q1 2025 financial results on May 12, 2025, followed by a conference call.
Quiver AI Summary
Harvard Bioscience, Inc. (Nasdaq: HBIO) will release its financial results for the first quarter of 2025 on May 12, 2025, before the market opens, followed by a conference call at 8:00 a.m. Eastern Time to discuss the results. Participants interested in joining the call must register to receive dial-in information and a unique PIN. An audio-only webcast will also be available on the company's investor website. Financial details, including the earnings release and a slide presentation, will be accessible on the Investor Relations section of Harvard Bioscience's website. The company develops and sells technologies for life science applications and serves a diverse range of customers worldwide.
Potential Positives
- Harvard Bioscience, Inc. will be disclosing its financial results for Q1 2025, providing transparency and insights into its performance.
- The scheduled conference call aims to engage with investors, indicating a commitment to shareholder communication and relationship building.
- The company highlights its broad customer base, which includes prestigious academic institutions and leading pharmaceutical organizations, demonstrating strong market positioning.
- Harvard Bioscience has a global operational footprint, with sales in the U.S., Europe, and China, showcasing its international presence and market reach.
Potential Negatives
- Company has not provided any financial guidance or predictions, which may raise concerns among investors about future performance.
- The announcement of financial results, rather than specific positive updates about business performance, could imply that there are underlying issues or a lack of growth.
- The requirement for participants to register to ask questions during the conference call may limit shareholder engagement and transparency.
FAQ
When will Harvard Bioscience announce its financial results?
Harvard Bioscience will announce its financial results on May 12, 2025, before the market opens.
What time is the conference call for financial results?
The conference call to discuss the financial results will be held at 8:00 a.m. Eastern Time.
How can I participate in the conference call?
Participants must register to join the call and ask questions, receiving dial-in numbers and a unique PIN.
Where can I find the financial information presented in the call?
The financial information will be available in the Investor Relations section of Harvard Bioscience’s website.
What products does Harvard Bioscience offer?
Harvard Bioscience develops technologies for life science applications, including research, pharmaceutical discovery, and preclinical testing.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$HBIO Hedge Fund Activity
We have seen 42 institutional investors add shares of $HBIO stock to their portfolio, and 40 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AMH EQUITY LTD added 887,355 shares (+35.5%) to their portfolio in Q1 2025, for an estimated $502,242
- 272 CAPITAL LP added 758,685 shares (+128.0%) to their portfolio in Q4 2024, for an estimated $1,600,825
- ROYCE & ASSOCIATES LP added 513,664 shares (+35.4%) to their portfolio in Q4 2024, for an estimated $1,083,831
- RUSSELL INVESTMENTS GROUP, LTD. removed 298,300 shares (-99.0%) from their portfolio in Q4 2024, for an estimated $629,413
- GRANAHAN INVESTMENT MANAGEMENT, LLC removed 248,251 shares (-13.3%) from their portfolio in Q4 2024, for an estimated $523,809
- GREENWOOD CAPITAL ASSOCIATES LLC removed 187,809 shares (-86.8%) from their portfolio in Q1 2025, for an estimated $106,299
- BOOTHBAY FUND MANAGEMENT, LLC removed 184,423 shares (-13.8%) from their portfolio in Q4 2024, for an estimated $389,132
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
HOLLISTON, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended March 31, 2025, before the market opens on May 12, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.
Participants who would like to join the call and ask a question must register here . Once registered, you will receive the dial-in numbers and a unique PIN number.
Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here .
Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website.
About Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.
For more information, please visit our website at www.harvardbioscience.com .
Company Contact:
Jennifer Cote
Chief Financial Officer
(508) 893-3120
[email protected]
